{"id":485,"date":"2026-03-04T17:37:56","date_gmt":"2026-03-04T12:07:56","guid":{"rendered":"https:\/\/www.najao.com\/learn\/?p=485"},"modified":"2026-04-02T18:03:46","modified_gmt":"2026-04-02T12:33:46","slug":"acute-respiratory-distress-syndrome-ards","status":"publish","type":"post","link":"https:\/\/www.najao.com\/learn\/acute-respiratory-distress-syndrome-ards\/","title":{"rendered":"Acute Respiratory Distress Syndrome: From Cytokine Storm to Precision Recovery"},"content":{"rendered":"\n

Acute Respiratory Distress Syndrome (ARDS) is one of the most severe<\/a> forms of acute respiratory failure, characterized by rapid onset of profound hypoxemia, diffuse inflammatory lung injury, and non-cardiogenic pulmonary edema. It affects roughly 10% of all intensive care unit admissions and up to one-third of patients requiring mechanical ventilation, thus posing a central challenge in critical care medicine1<\/sup><\/strong>. Even after many years of research, ARDS continues to cause significant morbidity and mortality, primarily because disease-modifying therapies have not kept pace with advancements in supportive care.<\/p>\n\n\n\n

Earlier, ARDS was dismissed simply as \u201cwet lungs.2<\/sup><\/strong>\u201d but now it is recognized as a biologically heterogeneous disorder in which dysregulated immune responses play a decisive role. A growing body of evidence shows ARDS isn’t just a localized lung condition. It’s a systemic inflammatory syndrome that the lung injury itself triggers and then amplifies throughout the body.<\/p>\n\n\n\n

The syndrome typically follows within a week of a major event, like sepsis, severe pneumonia, aspiration, or trauma3<\/sup><\/strong>. These events cause the abrupt disruption of the alveolar\u2013capillary barrier, which is the ultra-thin interface responsible for gas exchange4<\/sup><\/strong>. When this barrier fails, protein-rich fluid floods the alveoli, making them heavy, stiff, and prone to collapse. At the same time, inflammatory mediators leak into the bloodstream. This changes the lung from a passive target into an active driver of inflammation throughout the body. Clinically, this shows up as persistent hypoxemia and early dysfunction of distant organs, which cannot be solely explained by inadequate oxygenation.<\/p>\n\n\n\n

The cytokine storm as a driver of lung and multiorgan injury<\/h2>\n\n\n\n

Initiation of the inflammatory cascade<\/h3>\n\n\n\n

The cytokine storm is at the center of this systemic process5<\/sup><\/strong>. Following the initial lung injury, resident immune cells like alveolar macrophages initiate a powerful inflammatory cascade6<\/sup><\/strong>. This response recruits neutrophils, dendritic cells, and other immune populations, pushing cytokine release far beyond what the body can contain.<\/p>\n\n\n\n

Self-perpetuating immune dysregulation<\/h3>\n\n\n\n

Excessive activation of intracellular signaling pathways, like NF-\u03baB, JAK\/STAT, and MAPK, keep the inflammatory loop running7<\/sup><\/strong>. Instead of clearing the infection or injury, this dysregulated signaling damages the lung\u2019s delicate endothelial and epithelial barriers, promotes oxidative stress<\/a>, and causes more vascular leakage. It becomes a vicious cycle where inflammation causes injury, and that injury fuels even more inflammation.<\/p>\n\n\n\n

Cytokine spillover and multiorgan dysfunction<\/h3>\n\n\n\n

Importantly, the spillover of cytokines into the bloodstream explains why multiorgan failure, rather than just respiratory issues, is the leading cause of death in ARDS8<\/sup><\/strong>. These circulating mediators disrupt the blood\u2013brain barrier, weaken heart function, suppress bone marrow activity, and impair the kidneys. They also trigger microvascular clotting in the liver and kidneys. Viewing the cytokine storm as the link to multiorgan dysfunction provides a clear explanation for why the sickest patients decline so rapidly across their entire body.<\/p>\n\n\n\n

The biological stages of lung injury and repair<\/h2>\n\n\n\n

The exudative phase: inflammatory flooding and barrier failure<\/h3>\n\n\n\n

ARDS unfolds as a dynamic biological process rather than a single event. In the early exudative phase, which dominates the first week of illness, inflammatory fluid rapidly fills the alveoli. Damaged cells form hyaline membranes that coat the air spaces, which severely impairs gas exchange9<\/sup><\/strong>. During this phase, cytokine levels peak, leaving the lung both mechanically fragile and immunologically volatile.<\/p>\n\n\n\n

The proliferative phase: repair versus dysregulation<\/h3>\n\n\n\n

As the disease moves into the proliferative phase, the body attempts to restore the lung’s barriers and clear out the fluid9<\/sup><\/strong>. While many patients improve during this window, the repair process can become maladaptive in others. Persistent inflammatory signaling triggers fibroblasts to deposit excessive tissue, which sets the stage for permanent structural changes in the lung.<\/p>\n\n\n\n

The fibrotic phase: long-term structural remodeling<\/h3>\n\n\n\n

In a subset of patients, this process concludes in a fibrotic phase marked by permanent scarring and structural damage9<\/sup><\/strong>. The loss of flexible gas-exchange surfaces leads to long-term respiratory limitations, even for those who survive the acute illness.<\/p>\n\n\n\n

Precision phenotyping and biological diversity<\/h2>\n\n\n\n

Hyperinflammatory ARDS subphenotype<\/h3>\n\n\n\n

Research now shows that ARDS affects people in very different biological ways. Some patients experience an intense “hyperinflammatory” response that leads to much higher mortality rates10<\/sup><\/strong>. Because their bodies are reacting so aggressively, they often need a different treatment plan: like targeted steroids. However, for a patient with a milder inflammatory profile that wouldn’t be as effective.<\/p>\n\n\n\n

Hypoinflammatory ARDS subphenotype<\/h3>\n\n\n\n

On the other hand, some patients have a “hypoinflammatory” profile10<\/sup><\/strong>. Their bodies aren’t under the same level of intense stress, and they generally have better outcomes. For these patients, aggressive treatments meant for the sicker group could actually cause more harm than good. This explains why so many past drug trials failed; by treating everyone the same way, the benefits for one group were often canceled out by the risks to the other. Moving forward, using biomarkers<\/a> to identify a patient\u2019s specific type will be the key to making sure the treatment matches the actual biological need.<\/p>\n\n\n\n

Modern ventilatory management and the \u201cbaby lung\u201d concept of ARDS<\/h2>\n\n\n\n

Lung-protective ventilation strategies<\/h3>\n\n\n\n

In ARDS, large parts of the lung become flooded or collapsed, leaving only a small fraction of healthy tissue available for breathing. This remaining area, known as the “baby lung,” has to handle the full burden of mechanical stress from a ventilator11<\/sup><\/strong>. To protect it, doctors use “lung-protective ventilation,” which uses smaller breaths and carefully adjusted pressure to prevent the ventilator itself from causing further damage12<\/sup><\/strong>.<\/p>\n\n\n\n

Prone positioning and regional lung recruitment<\/h3>\n\n\n\n

Prone positioning is a highly effective way to manage severe ARDS13<\/sup><\/strong>. Rather than relying solely on the ventilator, flipping the patient onto their stomach helps the lungs work more efficiently by balancing out air and blood flow. This technique relieves the pressure on damaged tissues and has been proven to improve survival rates when applied as a consistent part of the treatment plan.<\/p>\n\n\n\n

Advanced rescue strategies and extracorporeal support in ARDS<\/h2>\n\n\n\n

Extracorporeal membrane oxygenation (ECMO)<\/h3>\n\n\n\n

When standard treatments aren’t enough to keep oxygen levels safe, ECMO can act as a life-saving bridge14<\/sup><\/strong>. By using a machine to do the work of the lungs, it gives them a chance to rest. This allows doctors to turn the ventilator settings down to a very gentle level, preventing the cycle of injury from getting worse and provides the time needed for the lungs to recover.<\/p>\n\n\n\n

Emerging immunomodulatory and cell-based therapies of ARDS<\/h2>\n\n\n\n

Corticosteroids and targeted immunomodulation<\/h3>\n\n\n\n

Corticosteroids are now a key part of treating moderate to severe ARDS because they can help blunt the body’s excessive immune response15<\/sup><\/strong>. However, timing is everything, as they work best when used at the right moment in the inflammatory process. Other advanced treatments, like targeted biologics and extracorporeal cytokine removal strategies, are still being studied16, 17<\/sup><\/strong>. Their success will likely depend on matching them to the right phenotype at the right stage of the disease.<\/p>\n\n\n\n

Cell-based therapies and extracellular vesicles<\/h3>\n\n\n\n

Mesenchymal stromal cells and their extracellular vesicles represent a significant area of emerging research18<\/sup><\/strong>. Instead of trying to physically replace damaged lung cells, these therapies work by sending signals to the body\u2019s own cells. They work by modulating immune responses, stabilizing endothelial barriers, and promoting tissue repair rather than direct cellular replacement.<\/p>\n\n\n\n

Artificial intelligence (AI) and the digital ICU<\/h2>\n\n\n\n

The future of ARDS care is becoming increasingly data-driven rather than relying solely on observation. Now, AI algorithms can analyze complex ventilator waveforms and lab results to identify subtle signs of lung stress19<\/sup><\/strong>. With these advancements, doctors are better equipped to classify patients into appropriate phenotypes and suggest optimal treatments at an earlier stage. This approach enables healthcare providers to be proactive rather than reactive in their care.<\/p>\n\n\n\n

Life after ARDS and the post-ICU burden<\/h2>\n\n\n\n

Survival from ARDS often marks the beginning of a prolonged recovery. For many survivors, leaving the ICU is just the first step in a journey that can last months or even years. While the lungs usually regain most of their function over a year, the long-term impact on the rest of the body can be significant. The Post-Intensive Care Syndrome (PICS) encompasses lasting muscle weakness, cognitive impairment, and emotional challenges like PTSD20<\/sup><\/strong>. This makes specialized rehabilitation and long-term follow-up care a necessity rather than an option to improve the quality of life.<\/p>\n\n\n\n

From cytokine storm to precision recovery<\/h2>\n\n\n\n

ARDS is more than just lung failure; it involves a complex interplay of immunological, mechanical, and technological factors. Targeting the cytokine storm and accounting for patient\u2011specific biology within a multi\u2011omics<\/a> framework allows for more personalized care<\/a>. By integrating molecular research, evidence-based lung-protective strategies, and AI<\/a>, the treatment approach is shifting from acute crisis management to a structured plan for sustained recovery.<\/p>\n\n\n\n\n\n\n\n

FAQs<\/h2>\n\n\n\n

1. Why is ARDS considered a systemic syndrome rather than just a lung disease?<\/h4>\n\n\n\n

Although ARDS originates in the lungs, it rarely stays there. When the lung’s barriers fail, the body’s inflammatory mediators and cytokines “spill over” into the rest of the body. These systemic spread triggers a “cytokine storm” that can travel through the bloodstream and damage distant organs like the kidneys, heart, and brain.<\/p>\n\n\n\n

2. What is the role of nutrition in ARDS recovery?<\/h4>\n\n\n\n

During the cytokine storm, the body burns calories at an incredible rate to sustain the immune response. Without early enteral nutrition (feeding via a tube to the stomach), the body begins to consume its own muscle tissue for fuel, specifically of the diaphragm, which can make it much harder for a patient to eventually breathe without help.<\/p>\n\n\n\n

3. How is ARDS distinguished from cardiogenic pulmonary edema?<\/h4>\n\n\n\n

While both conditions cause “fluid in the lungs,” they happen for very different reasons. In cardiogenic edema, fluid is “pushed” into the lungs because of high pressure from a failing heart. In ARDS, the fluid “leaks” in because the lung\u2019s protective lining is physically damaged by inflammation. Clinicians use echocardiograms or pulmonary artery catheters to confirm that the heart’s filling pressures are normal.<\/p>\n\n\n\n

Reference<\/h2>\n\n\n\n

1. Bellani, G., Laffey, J. G., Pham, T., et al<\/em>. (2016). Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. Jama<\/em>, 315<\/em>(8), 788-800.<\/p>\n\n\n\n

2. Villar, J. (2011). What is the acute respiratory distress syndrome?. Respiratory care<\/em>, 56<\/em>(10), 1539-1545.<\/p>\n\n\n\n

3. Sheu, C. C., Gong, M. N., Zhai, R., et al<\/em>. (2010). Clinical characteristics and outcomes of sepsis-related vs non-sepsis-related ARDS. Chest<\/em>, 138<\/em>(3), 559-567.<\/p>\n\n\n\n

4. Esquivel-Ruiz, S., Gonz\u00e1lez-Rodr\u00edguez, P., Lorente, J. A., et al<\/em>. (2021). Extracellular vesicles and alveolar epithelial-capillary barrier disruption in acute respiratory distress syndrome: pathophysiological role and therapeutic potential. Frontiers in Physiology<\/em>, 12<\/em>, 752287.<\/p>\n\n\n\n

5. Coperchini, F., Chiovato, L., Croce, L., et al<\/em>. (2020). The cytokine storm in COVID-19: An overview of the involvement of the chemokine\/chemokine-receptor system. Cytokine & growth factor reviews<\/em>, 53<\/em>(2020), 25-32.<\/p>\n\n\n\n

6. Vichare, R., & Janjic, J. M. (2022). Macrophage-targeted nanomedicines for ARDS\/ALI: promise and potential. Inflammation<\/em>, 45<\/em>(6), 2124-2141.<\/p>\n\n\n\n

7. Li, W., Li, D., Chen, Y., et al<\/em>. (2022). Classic signaling pathways in alveolar injury and repair involved in sepsis\u2010induced ALI\/ARDS: new research progress and prospect. Disease markers<\/em>, 2022<\/em>(1), 6362344.<\/p>\n\n\n\n

8. Dekker, A. B. E., Krijnen, P., & Schipper, I. B. (2016). Predictive value of cytokines for developing complications after polytrauma. World journal of critical care medicine<\/em>, 5<\/em>(3), 187.<\/p>\n\n\n\n

9. Meduri, G. U., & Eltorky, M. A. (2015). Understanding ARDS-associated fibroproliferation. Intensive care medicine<\/em>, 41<\/em>(3), 517-520.<\/p>\n\n\n\n

10. Xu, H., Sheng, S., Luo, W., et al<\/em>. (2023). Acute respiratory distress syndrome heterogeneity and the septic ARDS subgroup. Frontiers in immunology<\/em>, 14<\/em>, 1277161.<\/p>\n\n\n\n

11. Gattinoni, L., Marini, J. J., Pesenti, A., et al<\/em>. (2016). The” baby lung” became an adult. Intensive care medicine<\/em>, 42<\/em>(5), 663-673.<\/p>\n\n\n\n

12. Baedorf Kassis, E. N., Bastos, A. B., Schaefer, M. S., et al<\/em>. (2022). Adaptive support ventilation and lung-protective ventilation in ARDS. Respiratory Care<\/em>, 67<\/em>(12), 1542-1550.<\/p>\n\n\n\n

13. Scholten, E. L., Beitler, J. R., Prisk, G. K., et al<\/em>. (2017). Treatment of ARDS with prone positioning. Chest<\/em>, 151<\/em>(1), 215-224.<\/p>\n\n\n\n

14. Combes, A., Hajage, D., Capellier, G., et al<\/em>. (2018). Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. New England Journal of Medicine<\/em>, 378<\/em>(21), 1965-1975.<\/p>\n\n\n\n

15. Peter, J. V., John, P., Graham, P. L., et al<\/em>. (2008). Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. Bmj<\/em>, 336<\/em>(7651), 1006-1009.<\/p>\n\n\n\n

16. Al-Husinat, L. I., Azzam, S., Al Sharie, S., et al<\/em>. (2025). A narrative review on the future of ARDS: evolving definitions, pathophysiology, and tailored management. Critical Care<\/em>, 29<\/em>(1), 88.<\/p>\n\n\n\n

17. Tomescu, D., Popescu, M., Akil, A., et al<\/em>. (2023). The potential role of extracorporeal cytokine removal with CytoSorb\u00ae as an adjuvant therapy in Acute Respiratory Distress Syndrome. The International Journal of Artificial Organs<\/em>, 46<\/em>(12), 605-617.<\/p>\n\n\n\n

18. Wang, F., Li, Y., Wang, B., et al<\/em>. (2023). The safety and efficacy of mesenchymal stromal cells in ARDS: a meta-analysis of randomized controlled trials. Critical Care<\/em>, 27<\/em>(1), 31.<\/p>\n\n\n\n

19. Zhang, Z., Navarese, E. P., Zheng, B., et al<\/em>. (2020). Analytics with artificial intelligence to advance the treatment of acute respiratory distress syndrome. Journal of Evidence<\/em>\u2010Based Medicine<\/em>, 13<\/em>(4), 301-312.<\/p>\n\n\n\n

20. Sturgill, J. L., Mayer, K. P., Kalema, A. G., et al<\/em>. (2023). Post-intensive care syndrome and pulmonary fibrosis in patients surviving ARDS-pneumonia of COVID-19 and non-COVID-19 etiologies. Scientific Reports<\/em>, 13<\/em>(1), 6554.<\/p>\n","protected":false},"excerpt":{"rendered":"

Acute Respiratory Distress Syndrome is a systemic inflammatory syndrome where a cytokine storm disrupts the alveolar-capillary barrier, causing fluid accumulation and multiorgan dysfunction. Precision phenotyping distinguishes hyperinflammatory and hypoinflammatory subphenotypes, and guides treatments like lung-protective ventilation and prone positioning to manage the exudative and fibrotic phases for improved precision recovery.<\/p>\n","protected":false},"author":3,"featured_media":486,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13,8,15,18],"tags":[],"coauthors":[10,9],"class_list":["post-485","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biochemistry","category-healthcare","category-immunology","category-molecular-biology"],"yoast_head":"\nARDS: From Cytokine Storm to Precision Recovery<\/title>\n<meta name=\"description\" content=\"In ARDS, cytokine storm disrupts the alveolar-capillary barrier, causing fluid accumulation and multiorgan dysfunction.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.najao.com\/learn\/acute-respiratory-distress-syndrome-ards\/\" \/>\n<link rel=\"next\" href=\"https:\/\/www.najao.com\/learn\/acute-respiratory-distress-syndrome-ards\/2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ARDS: From Cytokine Storm to Precision Recovery\" \/>\n<meta property=\"og:description\" content=\"In ARDS, cytokine storm disrupts the alveolar-capillary barrier, causing fluid accumulation and multiorgan dysfunction.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.najao.com\/learn\/acute-respiratory-distress-syndrome-ards\/\" \/>\n<meta property=\"og:site_name\" content=\"Najao Inovix\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/najaoinovix\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-04T12:07:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-02T12:33:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.najao.com\/learn\/wp-content\/uploads\/2026\/04\/Acute-Respiratory-Distress-Syndrome.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sujay Ghosh, Anwesha Acharyya\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@najaoinovix\" \/>\n<meta name=\"twitter:site\" content=\"@najaoinovix\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sujay Ghosh, Anwesha Acharyya\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/acute-respiratory-distress-syndrome-ards\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/acute-respiratory-distress-syndrome-ards\\\/\"},\"author\":{\"name\":\"Sujay Ghosh\",\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/#\\\/schema\\\/person\\\/dce56c4224dfcacff6edf2e58f0f68d2\"},\"headline\":\"Acute Respiratory Distress Syndrome: From Cytokine Storm to Precision Recovery\",\"datePublished\":\"2026-03-04T12:07:56+00:00\",\"dateModified\":\"2026-04-02T12:33:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/acute-respiratory-distress-syndrome-ards\\\/\"},\"wordCount\":2163,\"publisher\":{\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/acute-respiratory-distress-syndrome-ards\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Acute-Respiratory-Distress-Syndrome.jpg\",\"articleSection\":[\"Biochemistry\",\"Healthcare\",\"Immunology\",\"Molecular Biology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/acute-respiratory-distress-syndrome-ards\\\/\",\"url\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/acute-respiratory-distress-syndrome-ards\\\/\",\"name\":\"ARDS: From Cytokine Storm to Precision Recovery\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/acute-respiratory-distress-syndrome-ards\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/acute-respiratory-distress-syndrome-ards\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Acute-Respiratory-Distress-Syndrome.jpg\",\"datePublished\":\"2026-03-04T12:07:56+00:00\",\"dateModified\":\"2026-04-02T12:33:46+00:00\",\"description\":\"In ARDS, cytokine storm disrupts the alveolar-capillary barrier, causing fluid accumulation and multiorgan dysfunction.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.najao.com\\\/learn\\\/acute-respiratory-distress-syndrome-ards\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/acute-respiratory-distress-syndrome-ards\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Acute-Respiratory-Distress-Syndrome.jpg\",\"contentUrl\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Acute-Respiratory-Distress-Syndrome.jpg\",\"width\":1024,\"height\":1024,\"caption\":\"Acute Respiratory Distress Syndrome (ARDS)\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/#website\",\"url\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/\",\"name\":\"Najao Inovix\",\"description\":\"Cooperation for Success\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/#organization\",\"name\":\"Najao Inovix\",\"url\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Najao-Favicon.png\",\"contentUrl\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/Najao-Favicon.png\",\"width\":2490,\"height\":2490,\"caption\":\"Najao Inovix\"},\"image\":{\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/najaoinovix\\\/\",\"https:\\\/\\\/x.com\\\/najaoinovix\",\"https:\\\/\\\/www.instagram.com\\\/najaoinovix\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/najao\\\/\",\"https:\\\/\\\/www.threads.com\\\/@najaoinovix\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/#\\\/schema\\\/person\\\/dce56c4224dfcacff6edf2e58f0f68d2\",\"name\":\"Sujay Ghosh\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/75020d47c7623402695f739d0e19add7e387d7645c2f867ea8bdd24f4d8e6f92?s=96&d=mm&r=g0181851cb7cff8a9fa8e05f03e21ab7b\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/75020d47c7623402695f739d0e19add7e387d7645c2f867ea8bdd24f4d8e6f92?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/75020d47c7623402695f739d0e19add7e387d7645c2f867ea8bdd24f4d8e6f92?s=96&d=mm&r=g\",\"caption\":\"Sujay Ghosh\"},\"url\":\"https:\\\/\\\/www.najao.com\\\/learn\\\/author\\\/sujay\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ARDS: From Cytokine Storm to Precision Recovery","description":"In ARDS, cytokine storm disrupts the alveolar-capillary barrier, causing fluid accumulation and multiorgan dysfunction.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.najao.com\/learn\/acute-respiratory-distress-syndrome-ards\/","next":"https:\/\/www.najao.com\/learn\/acute-respiratory-distress-syndrome-ards\/2\/","og_locale":"en_US","og_type":"article","og_title":"ARDS: From Cytokine Storm to Precision Recovery","og_description":"In ARDS, cytokine storm disrupts the alveolar-capillary barrier, causing fluid accumulation and multiorgan dysfunction.","og_url":"https:\/\/www.najao.com\/learn\/acute-respiratory-distress-syndrome-ards\/","og_site_name":"Najao Inovix","article_publisher":"https:\/\/www.facebook.com\/najaoinovix\/","article_published_time":"2026-03-04T12:07:56+00:00","article_modified_time":"2026-04-02T12:33:46+00:00","og_image":[{"width":1024,"height":1024,"url":"https:\/\/www.najao.com\/learn\/wp-content\/uploads\/2026\/04\/Acute-Respiratory-Distress-Syndrome.jpg","type":"image\/jpeg"}],"author":"Sujay Ghosh, Anwesha Acharyya","twitter_card":"summary_large_image","twitter_creator":"@najaoinovix","twitter_site":"@najaoinovix","twitter_misc":{"Written by":"Sujay Ghosh, Anwesha Acharyya","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.najao.com\/learn\/acute-respiratory-distress-syndrome-ards\/#article","isPartOf":{"@id":"https:\/\/www.najao.com\/learn\/acute-respiratory-distress-syndrome-ards\/"},"author":{"name":"Sujay Ghosh","@id":"https:\/\/www.najao.com\/learn\/#\/schema\/person\/dce56c4224dfcacff6edf2e58f0f68d2"},"headline":"Acute Respiratory Distress Syndrome: From Cytokine Storm to Precision Recovery","datePublished":"2026-03-04T12:07:56+00:00","dateModified":"2026-04-02T12:33:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.najao.com\/learn\/acute-respiratory-distress-syndrome-ards\/"},"wordCount":2163,"publisher":{"@id":"https:\/\/www.najao.com\/learn\/#organization"},"image":{"@id":"https:\/\/www.najao.com\/learn\/acute-respiratory-distress-syndrome-ards\/#primaryimage"},"thumbnailUrl":"https:\/\/www.najao.com\/learn\/wp-content\/uploads\/2026\/04\/Acute-Respiratory-Distress-Syndrome.jpg","articleSection":["Biochemistry","Healthcare","Immunology","Molecular Biology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.najao.com\/learn\/acute-respiratory-distress-syndrome-ards\/","url":"https:\/\/www.najao.com\/learn\/acute-respiratory-distress-syndrome-ards\/","name":"ARDS: From Cytokine Storm to Precision Recovery","isPartOf":{"@id":"https:\/\/www.najao.com\/learn\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.najao.com\/learn\/acute-respiratory-distress-syndrome-ards\/#primaryimage"},"image":{"@id":"https:\/\/www.najao.com\/learn\/acute-respiratory-distress-syndrome-ards\/#primaryimage"},"thumbnailUrl":"https:\/\/www.najao.com\/learn\/wp-content\/uploads\/2026\/04\/Acute-Respiratory-Distress-Syndrome.jpg","datePublished":"2026-03-04T12:07:56+00:00","dateModified":"2026-04-02T12:33:46+00:00","description":"In ARDS, cytokine storm disrupts the alveolar-capillary barrier, causing fluid accumulation and multiorgan dysfunction.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.najao.com\/learn\/acute-respiratory-distress-syndrome-ards\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.najao.com\/learn\/acute-respiratory-distress-syndrome-ards\/#primaryimage","url":"https:\/\/www.najao.com\/learn\/wp-content\/uploads\/2026\/04\/Acute-Respiratory-Distress-Syndrome.jpg","contentUrl":"https:\/\/www.najao.com\/learn\/wp-content\/uploads\/2026\/04\/Acute-Respiratory-Distress-Syndrome.jpg","width":1024,"height":1024,"caption":"Acute Respiratory Distress Syndrome (ARDS)"},{"@type":"WebSite","@id":"https:\/\/www.najao.com\/learn\/#website","url":"https:\/\/www.najao.com\/learn\/","name":"Najao Inovix","description":"Cooperation for Success","publisher":{"@id":"https:\/\/www.najao.com\/learn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.najao.com\/learn\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.najao.com\/learn\/#organization","name":"Najao Inovix","url":"https:\/\/www.najao.com\/learn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.najao.com\/learn\/#\/schema\/logo\/image\/","url":"https:\/\/www.najao.com\/learn\/wp-content\/uploads\/2025\/05\/Najao-Favicon.png","contentUrl":"https:\/\/www.najao.com\/learn\/wp-content\/uploads\/2025\/05\/Najao-Favicon.png","width":2490,"height":2490,"caption":"Najao Inovix"},"image":{"@id":"https:\/\/www.najao.com\/learn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/najaoinovix\/","https:\/\/x.com\/najaoinovix","https:\/\/www.instagram.com\/najaoinovix\/","https:\/\/www.linkedin.com\/company\/najao\/","https:\/\/www.threads.com\/@najaoinovix"]},{"@type":"Person","@id":"https:\/\/www.najao.com\/learn\/#\/schema\/person\/dce56c4224dfcacff6edf2e58f0f68d2","name":"Sujay Ghosh","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/75020d47c7623402695f739d0e19add7e387d7645c2f867ea8bdd24f4d8e6f92?s=96&d=mm&r=g0181851cb7cff8a9fa8e05f03e21ab7b","url":"https:\/\/secure.gravatar.com\/avatar\/75020d47c7623402695f739d0e19add7e387d7645c2f867ea8bdd24f4d8e6f92?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/75020d47c7623402695f739d0e19add7e387d7645c2f867ea8bdd24f4d8e6f92?s=96&d=mm&r=g","caption":"Sujay Ghosh"},"url":"https:\/\/www.najao.com\/learn\/author\/sujay\/"}]}},"_links":{"self":[{"href":"https:\/\/www.najao.com\/learn\/wp-json\/wp\/v2\/posts\/485","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.najao.com\/learn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.najao.com\/learn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.najao.com\/learn\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.najao.com\/learn\/wp-json\/wp\/v2\/comments?post=485"}],"version-history":[{"count":2,"href":"https:\/\/www.najao.com\/learn\/wp-json\/wp\/v2\/posts\/485\/revisions"}],"predecessor-version":[{"id":490,"href":"https:\/\/www.najao.com\/learn\/wp-json\/wp\/v2\/posts\/485\/revisions\/490"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.najao.com\/learn\/wp-json\/wp\/v2\/media\/486"}],"wp:attachment":[{"href":"https:\/\/www.najao.com\/learn\/wp-json\/wp\/v2\/media?parent=485"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.najao.com\/learn\/wp-json\/wp\/v2\/categories?post=485"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.najao.com\/learn\/wp-json\/wp\/v2\/tags?post=485"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.najao.com\/learn\/wp-json\/wp\/v2\/coauthors?post=485"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}